FR23C1024I1 - Composition stable d'une protéine anabolique osseuse qui est un analogue de pthrp, et ses emplois - Google Patents

Composition stable d'une protéine anabolique osseuse qui est un analogue de pthrp, et ses emplois

Info

Publication number
FR23C1024I1
FR23C1024I1 FR23C1024C FR23C1024C FR23C1024I1 FR 23C1024 I1 FR23C1024 I1 FR 23C1024I1 FR 23C1024 C FR23C1024 C FR 23C1024C FR 23C1024 C FR23C1024 C FR 23C1024C FR 23C1024 I1 FR23C1024 I1 FR 23C1024I1
Authority
FR
France
Prior art keywords
pthrp
analog
stable composition
bone protein
anabolic bone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR23C1024C
Other languages
English (en)
French (fr)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ipsen Pharma SAS
Radius Health Inc
Original Assignee
Ipsen Pharma SAS
Radius Health Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39430237&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR23C1024(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ipsen Pharma SAS, Radius Health Inc filed Critical Ipsen Pharma SAS
Publication of FR23C1024I1 publication Critical patent/FR23C1024I1/fr
Application granted granted Critical
Publication of FR23C1024I2 publication Critical patent/FR23C1024I2/fr
Active legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Materials For Medical Uses (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
FR23C1024C 2006-10-03 2023-06-05 Composition stable d'une protéine anabolique osseuse qui est un analogue de pthrp, et ses emplois Active FR23C1024I2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US84896006P 2006-10-03 2006-10-03
PCT/US2007/021216 WO2008063279A2 (en) 2006-10-03 2007-10-03 A stable composition comprising a bone anabolic protein, namely a pthrp analogue, and uses thereof

Publications (2)

Publication Number Publication Date
FR23C1024I1 true FR23C1024I1 (fr) 2023-07-21
FR23C1024I2 FR23C1024I2 (fr) 2024-06-14

Family

ID=39430237

Family Applications (1)

Application Number Title Priority Date Filing Date
FR23C1024C Active FR23C1024I2 (fr) 2006-10-03 2023-06-05 Composition stable d'une protéine anabolique osseuse qui est un analogue de pthrp, et ses emplois

Country Status (28)

Country Link
US (1) US8148333B2 (no)
EP (2) EP2957278B1 (no)
JP (1) JP5375611B2 (no)
KR (4) KR20150020289A (no)
CN (2) CN101578093B (no)
AU (1) AU2007322334B2 (no)
BR (2) BRPI0719821B8 (no)
CA (1) CA2664734C (no)
CY (1) CY1119198T1 (no)
DK (2) DK2957278T3 (no)
ES (2) ES2637283T3 (no)
FR (1) FR23C1024I2 (no)
HK (1) HK1214181A1 (no)
HR (1) HRP20171217T1 (no)
IL (1) IL197926A (no)
LT (1) LT2957278T (no)
MX (1) MX2009003569A (no)
NL (1) NL301235I2 (no)
NO (1) NO344885B1 (no)
NZ (1) NZ576682A (no)
PL (1) PL2957278T3 (no)
PT (2) PT2073789T (no)
RS (1) RS56164B1 (no)
RU (1) RU2506070C2 (no)
SG (1) SG175580A1 (no)
SI (1) SI2957278T1 (no)
UA (1) UA98776C2 (no)
WO (1) WO2008063279A2 (no)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE49444E1 (en) 2006-10-03 2023-03-07 Radius Health, Inc. Method of treating osteoporosis comprising administration of PTHrP analog
US7803770B2 (en) 2006-10-03 2010-09-28 Radius Health, Inc. Method of treating osteoporosis comprising administration of PTHrP analog
DK2957278T3 (en) 2006-10-03 2017-07-31 Radius Health Inc STABLE COMPOSITION COMPREHENSIVE PTHRP AND APPLICATIONS THEREOF
CA2799183A1 (en) 2010-05-12 2011-11-17 Radius Health, Inc. Therapeutic regimens
AU2011312490B2 (en) 2010-09-28 2015-06-25 Radius Pharmaceuticals, Inc. Selective androgen receptor modulators
EP2472328B1 (en) 2010-12-31 2013-06-19 Rohm and Haas Electronic Materials LLC Coating compositions for use with an overcoated photoresist
EP2472329B1 (en) 2010-12-31 2013-06-05 Rohm and Haas Electronic Materials LLC Coating compositions for use with an overcoated photoresist
AU2012245301B2 (en) * 2011-04-22 2016-05-19 3M Innovative Properties Company, A Wholly Owned Subsidiary Of 3M Company Method of drug delivery for PTH, PTHrP and related peptides
ES2833277T3 (es) 2011-06-07 2021-06-14 Asahi Kasei Pharma Corp Preparación liofilizada que contiene PTH de alta pureza y método para producirla
CN104080441B (zh) 2011-11-30 2020-02-28 3M创新有限公司 包括肽治疗剂和氨基酸的微针装置、制备和使用其的方法
IL255148B2 (en) 2015-04-29 2023-04-01 Radius Pharmaceuticals Inc 1901 rad for use in a method to inhibit a cancerous growth or induce tumor regression in a patient who is resistant to the drug and/or has cancer positive for an estrogen receptor alpha mutation
US20180161401A1 (en) * 2015-07-06 2018-06-14 Zheng Xin Dong Novel Formulations of PTHrP Analogue
TWI659991B (zh) 2015-08-31 2019-05-21 Rohm And Haas Electronic Materials Llc 與外塗佈光致抗蝕劑一起使用的塗料組合物
WO2017062922A1 (en) * 2015-10-09 2017-04-13 Radius Health, Inc. Formulations of pthrp analogues, transdermal patches thereof, and uses thereof
US10568937B2 (en) 2016-04-18 2020-02-25 Radius Health, Inc. Formulations of abaloparatide, transdermal patches thereof, and uses thereof
KR102397890B1 (ko) 2016-06-22 2022-05-12 일립시스 파마 리미티드 Ar+ 유방암 치료 방법
US20200317745A1 (en) * 2016-11-30 2020-10-08 Purdue Research Foundation Fracture targeted bone regeneration through parathyroid hormone receptor stimulation
KR102322802B1 (ko) 2017-01-05 2021-11-04 래디어스 파마슈티컬스, 인코포레이티드 Rad1901-2hcl의 다형 형태
US10996208B2 (en) 2017-04-28 2021-05-04 Radius Health, Inc. Abaloparatide formulations and methods of testing, storing, modifying, and using same
EP3765488A1 (en) * 2018-03-12 2021-01-20 Fresenius Kabi iPSUM S.r.l. Process for the manufacture of pthrp analogue
IL279853B1 (en) 2018-07-04 2024-09-01 Radius Pharmaceuticals Inc Polymorphic forms of RAD 1901-2HCL
EP4110371A1 (en) 2020-01-24 2023-01-04 Radius Health, Inc. Methods of stimulating bone growth with abalopartide and denosumab
WO2023281447A1 (en) 2021-07-07 2023-01-12 Radius Health, Inc. Methods of treating a cardiovascular ischemic event

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5821225A (en) 1992-07-14 1998-10-13 Syntex (U.S.A.) Inc. Method for the treatment of corticosteroid induced osteopenia comprising administration of modified PTH or PTHrp
US5589452A (en) 1992-07-14 1996-12-31 Syntex (U.S.A.) Inc. Analogs of parathyroid hormone and parathyroid hormone related peptide: synthesis and use for the treatment of osteoporosis
US5977070A (en) 1992-07-14 1999-11-02 Piazza; Christin Teresa Pharmaceutical compositions for the nasal delivery of compounds useful for the treatment of osteoporosis
NZ257212A (en) 1992-09-29 1996-11-26 Inhale Therapeutic Syst Parathyroid hormone formulations comprising a biologically active n-terminal fragment of the hormone
CN1070500C (zh) 1993-07-13 2001-09-05 森德克斯(美国)股份有限公司 甲状旁腺激素类似物和甲状旁腺激素相关肽：合成和治疗骨质疏松症的用途
US5723577A (en) 1995-07-13 1998-03-03 Biomeasure Inc. Analogs of parathyroid hormone
US7410948B2 (en) 1995-07-13 2008-08-12 Societe De Conseils De Recherches Et D'applications Scientifiques, Sas Analogs of parathyroid hormone
US5969095A (en) 1995-07-13 1999-10-19 Biomeasure, Inc. Analogs of parathyroid hormone
US5955574A (en) * 1995-07-13 1999-09-21 Societe De Conseils De Recherches Et D'applications Scientifiques, S.A. Analogs of parathyroid hormone
US6544949B1 (en) 1995-07-13 2003-04-08 Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S. Analogs of parathyroid hormone
CN1204262A (zh) * 1995-10-17 1999-01-06 曼海姆泊灵格股份公司 稳定的含甲状旁腺激素的药物给药剂型
TW505654B (en) 1996-07-30 2002-10-11 Hoffmann La Roche Synthesis of analogs of PTH and PTHrP
US6136784A (en) 1997-01-08 2000-10-24 Amylin Pharmaceuticals, Inc. Amylin agonist pharmaceutical compositions containing insulin
CZ298701B6 (cs) 1997-09-09 2007-12-27 F. Hoffman-La Roche Ag Lécivo pro hojení kostí a reparaci zlomenin
MY120063A (en) 1997-12-09 2005-08-30 Lilly Co Eli Stabilized teriparatide solutions
US6770623B1 (en) 1997-12-09 2004-08-03 Eli Lilly And Company Stabilized teriparatide solutions
SE9801495D0 (sv) 1998-04-28 1998-04-28 Astra Ab Protein formulationa
US6756480B2 (en) 2000-04-27 2004-06-29 Amgen Inc. Modulators of receptors for parathyroid hormone and parathyroid hormone-related protein
US20050124537A1 (en) 2000-04-27 2005-06-09 Amgen Inc. Modulators of receptors for parathyroid hormone and parathyroid hormone-related protein
US7371721B2 (en) * 2000-09-18 2008-05-13 Sanos Bioscience A/S Use of GLP-2 and related compounds for the treatment, prevention, diagnosis, and prognosis of bone-related disorders and calcium homeostasis related syndromes
AU2003251527A1 (en) * 2002-06-13 2003-12-31 Beth Israel Deaconess Medical Center, Inc. Analogs of parathyroid hormone and pth-related protein as bone anabolic agents
EP1567178A4 (en) 2002-11-01 2009-07-15 Amgen Inc MODULATORS OF RECEPTORS FOR NEUTRAL THERAPY HORMONE AND SIDE-HORSE HORMONE-RELATED PROTEINS
TWI359026B (en) 2004-02-12 2012-03-01 Sankyo Co Pharmaceutical composition for the osteoclast rela
CN101151048A (zh) * 2004-05-10 2008-03-26 纳斯泰克制药公司 增强甲状旁腺激素粘膜递送的组合物和方法
DK2957278T3 (en) 2006-10-03 2017-07-31 Radius Health Inc STABLE COMPOSITION COMPREHENSIVE PTHRP AND APPLICATIONS THEREOF
US7803770B2 (en) 2006-10-03 2010-09-28 Radius Health, Inc. Method of treating osteoporosis comprising administration of PTHrP analog

Also Published As

Publication number Publication date
NO344885B1 (no) 2020-06-15
CN101578093B (zh) 2011-09-14
CA2664734C (en) 2023-08-01
EP2957278B1 (en) 2017-05-17
UA98776C2 (ru) 2012-06-25
WO2008063279A2 (en) 2008-05-29
NZ576682A (en) 2012-08-31
EP2073789A2 (en) 2009-07-01
IL197926A (en) 2014-08-31
SG175580A1 (en) 2011-11-28
AU2007322334A1 (en) 2008-05-29
US20100029556A1 (en) 2010-02-04
WO2008063279A9 (en) 2008-07-10
EP2957278A1 (en) 2015-12-23
PT2073789T (pt) 2019-07-31
PL2957278T3 (pl) 2017-10-31
PT2957278T (pt) 2017-08-23
RS56164B1 (sr) 2017-11-30
MX2009003569A (es) 2009-08-25
CN101578093A (zh) 2009-11-11
DK2073789T3 (da) 2019-08-05
NO20091545L (no) 2009-05-27
KR20090083350A (ko) 2009-08-03
EP2073789B8 (en) 2022-09-14
IL197926A0 (en) 2011-08-01
NL301235I2 (nl) 2023-08-31
CN102274492A (zh) 2011-12-14
KR101512377B1 (ko) 2015-04-28
JP2010505835A (ja) 2010-02-25
BRPI0719821B1 (pt) 2020-04-14
JP5375611B2 (ja) 2013-12-25
RU2506070C2 (ru) 2014-02-10
KR20150020289A (ko) 2015-02-25
RU2009116531A (ru) 2010-11-10
CA2664734A1 (en) 2008-05-29
FR23C1024I2 (fr) 2024-06-14
HRP20171217T1 (hr) 2017-10-20
BRPI0719821A2 (pt) 2013-05-07
LT2957278T (lt) 2017-09-11
HK1214181A1 (zh) 2016-07-22
AU2007322334B2 (en) 2011-12-22
SI2957278T1 (sl) 2017-09-29
EP2073789B1 (en) 2019-05-22
CY1119198T1 (el) 2018-02-14
ES2739459T3 (es) 2020-01-31
BRPI0722428A2 (pt) 2013-11-26
CN102274492B (zh) 2014-11-26
US8148333B2 (en) 2012-04-03
KR20180117738A (ko) 2018-10-29
KR20170067906A (ko) 2017-06-16
WO2008063279A3 (en) 2009-06-25
BRPI0719821B8 (pt) 2021-05-25
ES2637283T3 (es) 2017-10-11
DK2957278T3 (en) 2017-07-31

Similar Documents

Publication Publication Date Title
FR23C1024I1 (fr) Composition stable d'une protéine anabolique osseuse qui est un analogue de pthrp, et ses emplois
EP1986674A4 (en) PROTEIN OR PEPTIDE COMPOSITIONS PROTEIN CONTAINING METHIONINE AND METHOD FOR MANUFACTURING AND USING SAME
BRPI0813699A2 (pt) Formulações de proteína de fusão glp-1-fc
IL218357A0 (en) Compositions and methods of using angiopoietin-like 4 protein
EP1874334A4 (en) COMPOSITIONS WITH BETA 2-GLYCOPROTEIN I-PEPTIDES FOR THE PREVENTION AND / OR TREATMENT OF VASCULAR DISEASES
ATE457736T1 (de) Zusammensetzung aus einem pulmonalen surfactant und einem von tnf stammenden peptid
EP2182006A3 (en) Compositions and methods for the treatment of immune related diseases
EP1487488A4 (en) SPECIFIC ANTIBODIES AGAINST AMYLOID BETA PEPTIDE, PHARMACEUTICAL COMPOSITIONS AND METHOD OF USE THEREOF
EP1765379A4 (en) CO-CRISTAL PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE THEREOF
IL196516A0 (en) Human endogenous retrovirus polypeptide compositions and methods of use thereof
PL1890720T3 (pl) Kompozycje farmaceutyczne zawierające peptydy pochodzące z kazeiny i sposoby ich stosowania
IL188288A0 (en) Polypeptide having an activity of suppressing food intake and pharmaceutical compositions containing the same
CL2007002619A1 (es) Compuestos derivados de 3-aza-biciclo[4.1.0]heptano; composicion farmaceutica; y uso en el tratamiento de la depresion.
EA200801244A1 (ru) Применение sdf-1 для лечения и/или профилактики неврологических заболеваний
CL2007003672A1 (es) Compuestos derivados de heteroaril-pirrolidinil-cetona y heteroaril-piperidinil-cetona; composicion farmaceutica; y uso en el tratamiento de la depresion y ansiedad.
DE602006007995D1 (de) Formulierungen von liponsäure und hyaluronsäurebeneichen
FR2949782B1 (fr) Peptide activateur de la transglutaminase et composition cosmetique ou pharmaceutique le contenant.
FR2925500B1 (fr) Peptide derive d'une proteine de la famille des aquaporines et composition cosmetique et/ou pharmaceutique le contenant
ITMI20021684A1 (it) Composizione farmaceutica di peptide nasale
FR2932680B1 (fr) Association de tiliroside et d'un peptide
FR2907681B1 (fr) Composition pharmaceutique et/ou cosmetique contenant des polypeptides ou des peptides.
WO2006120019A3 (en) Mcm9, a member of the mcm2-8 family and its use in pharmaceutical compositions
FR2946340B1 (fr) Nouveaux n-phenyl acetamie, inhibiteurs de l'enzyme soat-1, compositions pharmaceutiques et cosmetiques les contenant.
HUP0600489A2 (en) Use of echinacea or preparations made thereof for the manufacture of pharmaceutical compositions for the treatment of anxiety
ZA200710374B (en) Pharmaceutical compositions comprising casein derived peptides and methods of use thereof